Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the Western world. It is also the prototype of B-cell chronic lymphoid malignancies and of their ramifications within the fields of hematology, immunology and oncology. For a long time the Cinderella of lymphoid malignancies CLL has now become the focus of major interest and an increasing number of investigators from different areas, including genetics, molecular biology, basic and applied immunology are becoming actively engaged in the investigation of CLL. Clinicians are considering CLL as a very interesting target of many projects which aim at translating the new and exciting developments of basic science into effective new approaches to the patient.

Hematology is difficult to teach at the medical school level. The curriculum is necessarily fragmented across different years of study, and often separated considerably in time. Understanding hematology requires insight into several distinct aspects: applied physiology (generally taught early), an understanding of the essential pathological processes involving the blood are taught somewhat later (if at all), and the (necessarily) strong laboratory aspect is generally taught more or less concurrently with other clinical pathology topics, such as clinical chemistry and immunology. By the time the student is faced with blood diseases in the wards, the laboratory/pathological bias is well entrenched. It is thus difficult for the student to get an integrated view of the subject. The unspoken assumption, often reinforced by clinical tutors trained in the traditional perspective, is that blood tests are all that are required for a diagnosis in blood diseases.

The result has been that clinical expertise in blood diseases is generally poor. This is reflected in the importance given to the examination of the hematological system in most student primers. The hematological system, by and large, is almost completely neglected. Such relevant features such as pallor, jaundice, bleeding, splenomegaly and so on are dealt with either in passing or in relation first to another system or the general examination . It is almost as though it is taken for granted that the haematological system cannot be assessed clinically and yet, as demonstrated later in the book, it is in very many cases impossible to reach a complete haematological diagnosis without clinical assessment.

Effective, patient-centred care of hematological patients requires, as with all other patients, a comprehensive clinical insight into these disease processes, i.e. an integrated clinical and pathological approach. Added to these problems is the fact that the number of laboratory tests has increased explosively, and the laboratory simply does not have the time to attempt more than a brief, generalized, and increasingly, an automated interpretation of the results. Thus the onus of clinical interpretation necessarily falls more and more on the attending clinician, whose grounding in clinical haematology is too often inadequate, for the reasons mentioned.

Hematology is emerging as a clinical specialty in its own right. The training of hematology physicians today includes extensive clinical exposure (indeed they are expected to handle the clinical aspects themselves), while training of medical registrars requires considerable knowledge of haematology and its reports. Achieving an integrated approach would be made immeasurably easier by a book presenting the subject in a fully integrated, clinical way. This then has been the motivation for this book.

There is no shortage of hematological texts, some of them very good, and it would be presumptuous and self-indulgent to add to them without clear justification. However, practically all of the student-orientated texts tend still to teach hematology from a formal and largely static laboratory perspective, and the reports emanating from the laboratory tend to reinforce this. Many of the Crash Course types of hematology book on the market have (at least) two major weaknesses: they considerably oversimplify the subject, contributing to the very mechanistic and almost anti-intellectual approach to blood diseases and especially to the FBC and Hemostatic Screen; and they tend to concentrate on primary blood diseases, whereas in practice most abnormalities of the blood and in the FBC are secondary to disease outside the system that is to say, they work primarily from a pathological and not from a clinical viewpoint. The FBC is one of the most common and valuable tests in use; it is a relatively expensive test and generally speaking is poorly interpreted, and the potential wealth of information that can be gleaned is missed.

The approach described in this book is different from that in most student texts, and has been very successful in practice, starting almost from scratch, but omitting many of the basics such as the details of hematopoiesis, laboratory technology, and so on, which are hardly relevant to the practising clinician and student in the wards, and are primarily of interest to the hematologist and sometimes to the clinical specialist. Considerable emphasis is given to the clinical history and examination, and the interpretation of the clinical patterns thus exposed. Hopefully it will overcome many of the traditional problems experienced in practical diagnostic haematology.

All the practical essentials are covered, and effectively this book contains all the information the student will ever need, apart from details of therapy (until and unless they enter certain specialties).

The book is restricted to adult haematology, for practical reasons. While there are considerable areas of similarity between adult and paediatric haematology, there are also very significant differences. Thus, the only congenital diseases discussed in this book are those that can present after childhood and occasionally those that pose a significant problem in adult practice. Generally these are discussed only briefly. Often with these the assistance of a haematologist would have to be sought anyway. Sometimes even the haematologist may have to further consult someone sub-specializing in paediatric haematology."

In the era of personalized medicine, cancer treatment has become a model for the use of targeted therapeutics. Leaving behind the "one size fits all" approach to cancer care, this book provides the practicing oncologist with an overview of the advances in treatment and an understanding of the implementation of new therapeutic agents. Targeted Cancer Therapy is divided into twenty chapters covering specific hematologic malignancies and solid tumors, targeted and functional imaging, and combination therapies. Each disease specific chapter includes up-to-date information on investigational and FDA approved therapies which will enhance the reader s ability to prescribe effective drug regimens. This includes combinations of therapies and therapeutic modalities to overcome drug resistance.

In a rapidly changing field, this book will enable clinicians to improve their ability to practice personalized health planning, make early diagnoses, and select optimal drugs for each patient with predictable side effects and outcomes. Poised to change the landscape in oncology, Targeted Cancer Therapy is essential for practicing and academic physicians, fellows, and residents."

Emerging technologies in target identification, drug discovery, molecular markers, and imaging are rapidly changing the face of cancer. This book provides a foundation of knowledge in targeted cancer therapeutics. The treatment of cancer is increasingly being individualized, based on an understanding of underlying biologic mechanisms. Poised to change the landscape in oncology, this volume provides a state-of-the-art overview. It will be valuable to practicing and academic physicians, fellows, residents and students, as well as basic scientists, interested in the cancer field.

There is increasing recognition of the burden of venous thromboembolism (VTE) in patients with advanced incurable disease and the clinical, ethical, and philosophical challenges they may pose. With a growing elderly population and oncological therapies helping patients live longer with malignant disease, VTE is likely to be an ongoing problem. Whilst presentation, diagnosis, and treatment of VTE in general medicine is well established, its management within the palliative care setting is less clear-cut. Clinical presentation is often masked by other palliative symptoms, and symptoms can be consistent with those of other conditions; diagnosis is therefore underappreciated, and the condition can be difficult to manage.
Bringing together contributions from international experts in the field of VTE and palliative care, this book explores the increasing challenges faced by healthcare professionals when managing VTE in advanced disease. Topics such as the epidemiology and pathogenesis of the condition are discussed. It appraises the current evidence informing the prevention, diagnosis, and treatment of VTE, with particular emphasis on its application to patients with incurable malignancy and non-malignant disease. Chapters are illustrated with key learning points and, where appropriate, case studies are presented to illustrate the decision-making processes that may occur when balancing the evidence with its impact on patient quality of life.
This practical resource is invaluable for healthcare professionals working in all areas of medicine where patients with advanced cancer and non-malignant disease are cared for.

Red blood cells in humans-and most other mammals-have a tendency to form aggregates with a characteristic face-to-face morphology, similar to a stack of coins. Known as rouleaux, these aggregates are a normally occurring phenomenon and have a major impact on blood rheology. What is the underlying mechanism that produces this pattern? Does this really happen in blood circulation? And do these rouleaux formations have a useful function? The first book to offer a comprehensive review of the subject, Red Blood Cell Aggregation tackles these and other questions related to red blood cell (RBC) aggregates. The book covers basic, clinical, and physiological aspects of this important biophysical phenomenon and integrates these areas with concepts in bioengineering. It brings together state-of-the-art research on the determinants, mechanisms, and measurement and effects of RBC aggregation as well as on variations and comparative aspects. After an introductory overview, the book outlines factors and conditions that affect RBC aggregation. It presents the two hypotheses-the bridging model and the depletion model-that provide potential mechanisms for the adhesive forces that lead to the regular packing of the cells in rouleaux formations. The book also reviews the methods used to quantify RBC aggregation in vitro, focusing on their importance in clinical practice. Chapters discuss the effect of RBC aggregation on the in vitro rheology of blood as well as on tube flow. The book also looks at what happens in the circulation when red blood cells aggregate and examines variations due to physiological and pathophysiological challenges. The concluding chapter explores the formation of red blood cell aggregates in other mammals. Written by leading researchers in the field, this is an invaluable resource for basic science, medical, and clinical researchers; graduate stu

This book contains contributions of leading international scientists who participated at the NATO-ASI conference Stem cells and their potential for clinical application that was held in Kiev and Simeiz (Ukraine) from August 23 - 31, 2006. The articles cover a broad range of hot topics in stem cell and leukaemia research. These include the potential of various stem cell types in regenerative and transplantation medicine, different mechanisms of malignant transformation leading to leukaemia development, as well as novel clinical strategies for malignant disease treatment such as adoptive immunotherapy with gene-modified lymphocytes. The mixture of articles by principal scientists from Northern America, as well as Eastern and Western Europe, provides a comprehensive overview on area such as stem cell research, immunotherapy and gene therapy. Thus, this compilation should be valuable for readers interested in modern biomedicine who have background knowledge in those areas.

Alex Dowsett’s pulsating autobiography lifts the lid on a decade of life in the world’s greatest pelotons and tells how he succeeded despite being the world’s only top sportsperson with haemophilia A. For over a decade Alex Dowsett had been one of Britain’s best cyclists. He has ridden Grand Tours and Classics for elite teams including Sky and Movistar and broke the iconic World Hour Record – the ultimate time trial challenge. With humour, insight and brutal honesty, Alex tells of the challenges he has faced in his struggle to reach the top and his years as a pro-cyclist. Alex has achieved all this despite being the only top sportsperson in the world with haemophilia A. He describes how the condition – in which falls can be fatal – blighted his young sporting life, and his determination to succeed in cycling. Amazingly, he went on to excel in a sport in which cuts, grazes and bruises are a given. Every professional cyclist requires courage, but Alex takes fearlessness to another level. With an allstar cycling cast, including Bradley Wiggins, Chris Froome, Lance Armstrong and Mark Cavendish, this pulsating book lifts the lid on life in the peloton at the world’s top level. Open and frank in his views, Alex recalls his highs – including his coming of age time trial victory, a famous Giro d’Italia stage victory riding solo for 18 kilometres and famously breaking the World Hour record in 2015 – as well as his frustrations at the injustices he faced in the sport. Alex announced his forthcoming retirement at the end of the 2022 season and this memoir perfectly chronicles a career in which he was driven equally by love and rage. His compelling personal story combines with his take on being part of the golden age of British cycling and his sometimes outspoken views to produce an inspirational story of sporting endeavour.

Thrombotic disorders of the circulatory system represent the leading cause of morbidity, motality, and health care expenditure in the United States. Fibrinolytic and Antithrombotic Therapy provides a practical, evidence-based approach to the management of thrombotic disorders for all clinicians involved in the care of patients with these disorders. It provides not only vital conceptual information on fibrinolytic and antithrombotic therapy, but also the means to apply it to everyday decision making and patient care. Focusing on managment guidelines and critical pathways, the text stresses practicality and usability. It will be a valuable resource for the wide range of clinicians involved in the care of patients with these disorders, including cardiologists, emergency physicians, primary care physicians, hematologists, neurologists, intensivists, pharmacists, and nurse practitioners.
The origins of mammalian blood coagulation can be traced back over 400 million years. Despite its long history, it is only within the past century that this complex and pivotal teleologic system has begun to be understood. Most recently, the intricacies of hemostasis and pahtologic thrombosis have come to light, leading the way toward new, more effective, and safer treatment modalities.
The Second Edition of Fibrinolytic and Antithrombotic Therapy, even more concise and clinically relevant than the First, provides vital, evidence-based information on management of patients with arterial and venous thrombotic disorders. Since the First Edition, the text has been expanded to cover the evolving topics of atherothrombosis, thrombocardiology, hematologic/thrombophilic conditions, and vascular medicine. Itincludes up-to-date guidelines for antithrombotic and fibrinolytic therapy, and offers concise summaries of current "standards of care." Chapters are dedicated to discussions of patient-specific therapeutics and to the importance of genomics, proteomics, and metabolomics in defining genotype-phenotype relationships, while throughout the book coagulation, inflammation, and vascular medicine are newly examined as elements in an intricatley-linked triad of biochemical and cellular based phenomenology.

Get a quick, expert overview of hematologic and non-hematologic malignancies for which hematopoietic cell transplantation is a treatment option. Drs. Qaiser Bashir and Mehdi Hamadani provide easy-to-find information on basic science of hematopoietic cell transplantation, pharmacology, workflows and procedures, possible complications and side effects, in addition to the role of HCT in conjunction with clinical cellular therapy. Discusses high-dose chemotherapeutic regimens and radiation therapy, patient and donor selection and workup, as well as other key aspects of hematopoietic cell transplantation. Includes practical information on complications, infectious disease, and special populations such as patients with HIV infection. Consolidates today's available information in this fast-changing area into one convenient resource.

The modern rehabilitation medicine is an important part of the comprehensive me- cal attendance of hemophiliacs. The necessary multidisciplinary team of specialists is available in a qualitative high-class rehabilitation hospital. Indispensable is the point that the coordinating medical specialist in Rehabilitation Medicine on site is skilled in the treatment of hemophiliacs. But he doesn't want and he can't replace the patient's hematologist. He is just the coordinator of the comprehensive team in the rehabilitation clinic. I hope I have shown that rehabilitation is an important topic for most patients with hemophilia. References 1. Neuntes Sozialgesetzbuch (SGB IX) - Rehabilitation und Teilhabe behinderter Menschen - vom 19. 6. 2001 (BGBl. I,S. 1046) 2. Kurth A, Kreuz W, Scharrer I: "Die orthopadische Behandlung von muskulo-skelettalen Komplikationen der Hamophilie". Dtsch Arztebl 2002; 99: A 2928-2935 [Heft 44] 3. BAR: Wegweiser - Rehabilitation und Teilhabe behinderter Menschen,11. Auflage,Fra- furt/Main 2001 4. BAR und Sozialpsychologisches Institut (Koln): Teamentwicklung in der Rehabilitation, Franfurt/Main Juni 2000 5. Buzzard B, Beeton K: "Physiotherapy, Management of Haemophilia", Blackwell Science, Oxford 2000 6. Rizzo Battistella L: "Rehabilitation in Haemophilia - options in the developing world", Haemophilia, 1998, 4, 486-490 7. Beeton K S: "Physiotherapie bei erwachsenen Patienten mit Hamophilie". In Rodriguez- Merchan E C,Goddard N J u. Lee C A (Hrsg): Orthopadische Aspekte der Hamophilie,Stork Medien,Bruchsal 2002 (dt. Ubersetzung) 8.

Karl Landsteiner is best known for his discovery of the human blood goups. The revolutionary discoveries of this brilliant scientist in other fields have not received the recognition they deserve. His demonstration that poliomyelitis is transmissable showed the way of modern virology. His studies opening the field for epitope recognition, which he himself considered his main achievement, laid the foundation for research ongoing in our days. This book with its outstanding contributors is but a small tribute to this visionary scientist.

This volume covers the most important aspects of cerebral blood flow (CBF) from bench to bedside. It first defines the basic physiology of CBF, those qualities that make it unique or are shared with other organs and their clinical implications. There follows a section on CBF pathophysiology that explores many of the known and proposed mechanisms of cerebral ischemia in stroke and trauma states. The third section describes the numerous and powerful means available to measure blood flow, tissue function and overall perfusion. These are essential measures if one is to assess the effectiveness of therapies aimed at preventing or reversing cerebral ischemia. The final section describes the interesting and often successful recent clinical trials aimed at preventing or reversing cerebral ischemia. This collection of multicenter trial data and their implications in one volume is unique in this field. This book addresses all the major aspects of CBF from basic issues to clinical practice.

Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have."

The colony-stimulating factors (CSFs) are the major regulators in the body of the production and activity of two types of white blood cells - granulocytes and macrophages. This book provides a detailed account of the discovery of the CSFs, their structure, molecular biology and cellular receptors, the biology of the CSFs in vivo and in vitro and their present and future clinical applications. Written by two of the pioneers in the discovery of CSFs, it is a clear and well-illustrated survey of the history, knowledge and future directions of this exciting field of investigation, and serves also as a guide to the more general areas of growth factor and cytokine research. It will prove an invaluable review for cell biologists interested in how growth factors act on the body, as well as for clinicians applying the fruits of modern biotechnology to improved patient care.

This work is not an anatomical atlas nor textbook (like that of McAlpine and Anderson) nor an angiographical atlas (like that of Vlodaver et al.); it is a short and comprehensive survey of the many variations of the intrinsic cardiac vessels. The reader's attention is focused on the numerous structural details and peculiarities of the human coronary arteries. The many unique features have been revealed by meticulous dissection and present an excellent documentation. All in all, this study represents an up-to-date review of morphology of the coronary arteries.

This book contains the contributions to the 32nd Hemophilia Symposium, Hamburg 2001. The main topics are epidemiology, hemophilia, pediatric hemostasiology. The volume is rounded off by numerous free papers and posters on hemophilia, hemorrhagic diathesis, thrombophilic diathesis and associated topics.

This book contains the contributions to the 30th Hemophilia Symposium, 1999. The main topics are HIV infection, inhibitors in hemophilia, modern treatment of hemophilia, drug-induced thrombophilia and pediatric hemostasiology. The volume is rounded off by numerous free papers and posters on hemophilia and associated topics.

Because of their therapeutic safety, hydroxyethylstarch, gelatin and dextrans are among the most frequently used drugs in the world. Recent studies have shown that bleeding disorders, anaphylactic reactions and storage in the body depend decisively on the nature of the administered plasma substitute. Through interdisciplinary cooperation the "First European Volume Replacement Conference" has established indications for the use of individual plasma substitutes to improve the efficacy and therapeutic safety of volume replacement therapy.

Febrile neutropenia is a common complication in cancer patients and has been studied for more than 30 years. This is a field of cancer in which much progress in supportive care has been made, significantly reducing the morbidity and mortality from infections. Tremendous numbers of patients have already benefited from specific antineoplastic therapy and an even greater number could benefit from the prevention of infection or from the allevation of symptoms as a result of effective prophylaxis or adequate therapeutic strategies. This book evaluates the achievements in the past and identifies the major existing problems. It gives an overview of therapeutic possibilities and presents new concepts and strategies for making further progress.

Interferons were among the first cytokines to be studied clinically in recombinant form in the 1980s, beginning a new era of pharmacotherapy in internal medicine. Interferons were soon employed in the treatment of tumors and it was shown that those hematopoietic neoplasias which had been difficult to treat with chemotherapy responded well to interferon treatment. In the present volume, renowned international authors update the importance of interferons in various fields of internal medicine, dermatology, and urology. The book also contains a general introduction into the classification, structure, and mode of action of interferons. Further chapters discuss the range of side effects of these substances and point out possible focuses of further clinical interferon research.

The science of blood groups was born at the beginning of this century, when the field of immunology married that of genetics. Most of the subsequent progress in immunogenetics was achieved by British investigators. The six consecutive editions of the unequaled Blood Groups in Man have long been considered as the bible of blood groupers. It is quite unfortunate that this book has not been revisited since 1975. Although one cannot do without immunogenetics, which remains useful for the identification of new blood groups and genetic studies, the focus of interest has moved somewhat today. After several decades, the molecular basis of blood groups can be investigated by biochemists. From 1950 to 1980, the ABO, Hh, and Lewis blood groups served as models and their chemical basis came to be established. The red cell membrane glycophorins carrying the MN and Ss antigens and the glycolipids with P blood group specificities were also identified and characterized. The chemical basis of the other groups, however, remained largely unknown.

This book provides a state-of-the-art description of the current status of leukodepleted blood products. Advances in technology, particularly filtration, have achieved great success in the selective removal of these white cells. This has created a new challenge - the enumeration of white cells at low concentrations in filtered products. There may be benefits of the removal of such white cells on the quality of stored red cells and platelets. Improved safety may manifest as the attenuation of febrile reactions and reduction in sensitization to HLA antigens, viral disease transmission, transfusion associated immunomodulation, transfusion-related lung injury and reperfusion injury. Since white cell removal presents logistic problems and has cost implications, a cost-benefit analysis is essential to gauge the economic benefit of this approach. All of these aspects of white cell depleted products are discussed by acknowledged experts.

th This volume comprises the Proceedings of the 15 Congress of the International Society of Forensic Haemogenetics (ISFH), held for the first time in Venezia Lido, th th Italy, on 13 -15 October 1993. The abstracts of the scientific contributions sent to the Congress have been sub divided into chapters with numbers and headings corresponding to the Congress sessions listed in the final programme. A general index of all authors, in alpha betical order, is given at the end of the book. The book consists of 188 contributions and addresses several problems presently being discussed in forensic haemogenetics. The main portion is, of course, devoted to DNA technology: present and future trends in DNA method ology, DNA polymorphisms in paternity testing and in criminal investigation, DNA sequencing, PCR methodology, quality control and quality assurance. Data have been accumulated on population genetics and biostatistics. A new look has been given at old friends, with important contributions on the molecular biology of classical markers. Conventional genetic markers have been studied. Problems connected with genetic typing and human rights have been dealt with in depth, and the history and geography of human genes have been elucidated."

In 1989, the First International Symposium on Cytokines in Hemopoiesis, Oncology, and AIDS was held in Hanover, FRG. Since then there has been an explosion of knowledge in this field. New cytokines have been discovered, on which data are presented in this book, and receptors have already been cloned for many cytokines. In clinical application, some cytokines such as TNF have almost completely left the stage, but this may not be for ever. Enormous progress has been made in the field of hemopoietic growth factors, for which clinical studies from phase I to phase III have been conducted, and some of which have even been registered for routine use. In spite of this rapid development our knowledge of how to clinically exploit the effects of cytokines is very limited and lies far behind the advances made in basic research. Even for the hemopoietic growth factors, questions regarding the effect of adjuvant therapy on survival and or on general outcome in chemother apy have still not been answered. Discussion and exchange between those involved in basic science and clinical research is still urgently needed. We hope to successfully contribute to this process by continuing the series proceedings of the International Symposia on Cytokines in Hemopoiesis, Oncology, and AIDS. Hannover, in July 1992 Mathias Freund Hartmut Link Reinhold E. Schmidt Karl Welte List of Contributors Abbadessa, V. Istituto die Clinica Medica III, Centro Interdipartimenta de Ii Ricerche in Oncologia Clinica, 90100 Palermo, Italy Abecassis, M."